Sun Pharmaceutical Industries has secured approval for the topical formulation of Fluocinolone Acetonide based on the company’s ANDA 209336, solidifying its footprint in the corticosteroid space. The authorization is expected to drive incremental sales for the generic brand as it captures share from the parent drug, while also reducing wholesale acquisition costs for payers and patients.